BFRG BULLFROG AI HOLDINGS

Join BullFrog AI’s Exclusive Live Investor Webinar and Q&A Session on July 23

Join BullFrog AI’s Exclusive Live Investor Webinar and Q&A Session on July 23

GAITHERSBURG, Md., July 18, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics,, is pleased to invite investors to a webinar on July 23, 2025, at 4:15 p.m. ET.

The exclusive event, hosted by RedChip Companies, will feature BullFrog AI’s Founder and CEO, Vin Singh. Attendees will gain insights into BullFrog AI’s pioneering role in transforming drug discovery and development through its scalable, AI-driven platforms, including the newly launched BullFrog Data Networks™ Solutions Library, powered by the proprietary bfLEAP™ causal AI engine. Recently expanded with the launch of bfPREP™, a cutting-edge module designed to automate data cleansing and standardization, the Solutions Library offers clients a flexible, plug-and-play toolkit for every phase of the drug development lifecycle. Investors will also learn about BullFrog AI’s strategic global collaborations, including its partnership with leading CRO Sygnature Discovery, which is expected to drive significant revenue growth by expanding the commercial reach of BullFrog Data Networks™ internationally. The company's agile business model and robust recurring revenue potential position BullFrog AI to scale effectively within the rapidly evolving $204 billion biopharma R&D market.

A live question and answer session will follow the presentation.

To register for the free webinar, please visit:

Questions can be pre-submitted to or online during the live event.

About BullFrog AI

BullFrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP™ platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.

For more information visit BullFrog AI at: .

Safe Harbor Statement

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," “could,” “will,” "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners’ ability to market and sell our offerings and services, including BullFrog Data Networks™ and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Contact:

Dave Gentry

RedChip Companies, Inc.

1-407-644-4256



EN
18/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BULLFROG AI HOLDINGS

 PRESS RELEASE

Join BullFrog AI’s Exclusive Live Investor Webinar and Q&A Session on ...

Join BullFrog AI’s Exclusive Live Investor Webinar and Q&A Session on July 23 GAITHERSBURG, Md., July 18, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics,, is pleased to invite investors to a webinar on July 23, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature BullFrog AI’s Founder and CEO, Vin Singh. Attendees will gain insights into BullFrog AI’...

 PRESS RELEASE

BullFrog AI Launches bfPREP, a New AI-Powered Data Preparation Module ...

BullFrog AI Launches bfPREP, a New AI-Powered Data Preparation Module in Its BullFrog Data Networks Solutions Library New module addresses multi-billion-dollar data quality challenge in life sciences by automating data cleansing, standardization, and transformation for AI readiness Built for scale, security, and human in the loop domain expertise, the enterprise-wide solution is poised to transform drug development for the world’s largest biopharma organizations  GAITHERSBURG, Md., July 17, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-en...

 PRESS RELEASE

BullFrog AI Unveils BullFrog Data Networks™ Solutions Library, Expandi...

BullFrog AI Unveils BullFrog Data Networks™ Solutions Library, Expanding Scalable AI-Powered Biomedical Insight Platform to Large Enterprises New Data Networks Solutions Library includes native deployment support across Google Cloud Platform, Microsoft Azure, and Amazon Web Services Built for scale, security, and domain expertise, the enterprise-wide solution is poised to transform drug development for the world’s largest biopharma organizations GAITHERSBURG, Md., July 10, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug develop...

 PRESS RELEASE

BullFrog AI’s Dr. Juan Felipe Beltrán to Highlight Advanced AI Strateg...

BullFrog AI’s Dr. Juan Felipe Beltrán to Highlight Advanced AI Strategies in Bioinformatics at XTalks Webinar GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Dr. Juan Felipe Beltrán, Director of AI, Machine Learning, and Innovation, will be the featured speaker at the upcoming XTalks webinar: . Vin Singh, Founder and CEO of BullFrog A...

 PRESS RELEASE

BullFrog AI Announces Strategic Collaboration with Sygnature Discovery...

BullFrog AI Announces Strategic Collaboration with Sygnature Discovery to Introduce BullFrog Data Networks™ to Global Biopharma Clients GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced a strategic collaboration with Sygnature Discovery, a leading UK-based contract research organization (CRO) specializing in drug discovery. Through this collabo...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch